CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome
Metrics: PDF 2610 views | HTML 2608 views | ?
Erika Ortolan1,*, Alice Giacomino1,*, Francesca Martinetto1, Simona Morone1, Nicola Lo Buono1, Enza Ferrero1, Giorgio Scagliotti2,5, Silvia Novello2, Sara Orecchia3, Enrico Ruffini4, Ida Rapa2, Luisella Righi2, Marco Volante2 and Ada Funaro1,5
1 Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino, Italy
2 Department of Oncology, University of Torino, San Luigi Hospital, Orbassano, Italy
3 Pathology Unit, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
4 Department of Surgery, Section of Thoracic Surgery, University of Torino, Torino, Italy
5 Interdepartmental Center “G. Scansetti” for Studies on Asbestos and other Toxic Particulates, University of Torino, Torino, Italy
* These authors equally contributed to this work
Ada Funaro, email:
Keywords: mesothelioma, CD157/BST1, mTOR, tumor progression, chemotherapy resistance, prognostic marker
Received: May 26, 2014 Accepted: July 06, 2014 Published: July 08, 2014
Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging. There is an urgent need to advance our understanding of mesothelioma biology and to identify new molecular markers for improving management of patients. CD157 is a membrane glycoprotein linked to ovarian cancer progression and mesenchymal differentiation. The common embryonic origin of ovarian epithelial cells and mesothelial cells and the evident similarities between ovarian and mesothelial cancer prompted us to investigate the biological role and clinical significance of CD157 in malignant pleural mesothelioma (MPM).
CD157 mRNA and protein were detected in four of nine MPM cell lines of diverse histotype and in 85.2% of MPM surgical tissue samples (32/37 epithelioid; 37/44 biphasic). CD157 expression correlated with clinical aggressiveness in biphasic MPM. Indeed, high CD157 was a negative prognostic factor and an independent predictor of poor survival for patients with biphasic MPM by multivariate survival analysis (HR = 2.433, 95% CI 1.120-5.284; p = 0.025). In mesothelioma cell lines, CD157 gain (in CD157-negative cells) or knockdown (in CD157-positive cells) affected cell growth, migration, invasion and tumorigenicity, most notably in biphasic MPM cell lines. In these cells, CD157 expression was associated with increased activation of the mTOR signaling pathway, resulting in decreased platinum sensitivity. Moreover, a trend towards reduced survival was observed in patients with biphasic MPM receiving postoperative platinum-based chemotherapy. These findings indicate that CD157 is implicated in multiple aspects of MPM progression and suggest that CD157 expression could be used to stratify patients into different prognostic groups or to select patients that might benefit from particular chemotherapeutic approach.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.